Artivion (AORT) Expected to Announce Earnings on Thursday

Artivion (NYSE:AORT) is expected to be posting its quarterly earnings results before the market opens on Thursday, February 20th. Analysts expect Artivion to post earnings of $0.12 per share and revenue of $100.82 million for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

Artivion Stock Performance

Shares of AORT stock opened at $29.85 on Thursday. The company has a market cap of $1.25 billion, a P/E ratio of -1,492.50 and a beta of 1.75. The business has a 50 day moving average of $29.76 and a two-hundred day moving average of $27.62. Artivion has a 52 week low of $16.80 and a 52 week high of $32.33. The company has a quick ratio of 1.33, a current ratio of 1.88 and a debt-to-equity ratio of 0.71.

Insider Activity at Artivion

In other Artivion news, SVP Jean F. Holloway sold 8,070 shares of the company’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $30.12, for a total value of $243,068.40. Following the completion of the sale, the senior vice president now directly owns 153,862 shares in the company, valued at $4,634,323.44. This represents a 4.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CAO Amy Horton sold 4,329 shares of Artivion stock in a transaction on Friday, December 6th. The shares were sold at an average price of $29.66, for a total value of $128,398.14. Following the transaction, the chief accounting officer now owns 135,660 shares in the company, valued at approximately $4,023,675.60. This trade represents a 3.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 20,017 shares of company stock worth $600,007 in the last three months. 8.10% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. JMP Securities restated a “market outperform” rating and set a $33.00 price objective on shares of Artivion in a research report on Tuesday, December 10th. Oppenheimer boosted their price target on shares of Artivion from $30.00 to $32.00 and gave the company an “outperform” rating in a report on Friday, November 8th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $34.00 price objective on shares of Artivion in a report on Tuesday, January 28th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $31.80.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.